Takashi Kuwayama
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Takashi Kuwayama has a total of 103 co-authors. Here are the top co-authors by number of shared publications:
- Sadako Akashi-Tanaka
Department of Breast Surgical Oncology, Showa University School of Medicine, Tokyo, Japan
4 shared publications Chie Watanabe
Showa University School of Nursing and Rehabilitation Sciences: Showa Daigaku Daigakuin Hoken Iryogaku Kenkyuka Hoken Iryo Gakubu
3 shared publications- Kanae Taruno
Division of Breast Surgical Oncology, Department of Surgery, Showa Medical University School of Medicine, Tokyo, Japan
3 shared publications Seigo Nakamura
Showa University School of Medicine
3 shared publications- Seigo Nakamura
Division of Breast Surgical Oncology, Department of Surgery, Showa University School of Medicine, Shinagawa, Japan
3 shared publications - Hiroko Masuda
Department of Breast Surgery, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan
2 shared publications
Latest Publications
- 8 July 2026
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 218 (1) , 3
Efficacy and safety of eribulin mesylate vs. docetaxel or paclitaxel, combined with trastuzumab and pertuzumab, as first-line treatment for HER2-positive locally advanced or metastatic breast cancer: updated subgroup analyses of JBCRG-M06/EMERALD
Purpose We performed updated subgroup analyses of the EMERALD study to investigate efficacy, safety, and quality of life (QoL) in patients treated with eribulin (E) vs. either docetaxel (DTX) or paclitaxel (PTX). Methods Patients with HER2+ locally advanced/metastatic breast cancer (LABC/MBC) were randomized to receive E or taxane (T) (physician’s choice of DTX or PTX; declared in advance at registration) in 21-day cycles, each combined with trastuzumab + pertuzumab. Survival outcomes, treatment patterns, antitumor efficacy, safety, and QoL were examined. Results The intention-to-treat (and safety) populations comprised 224 (224) patients who received E, 186 (184) who received DTX, and 36 (34) who received PTX. Baseline characteristics were balanced. Progression-free survival (E vs. DTX: 14.0 vs. 13.1 months; hazard ratio [HR], 0.94 [95% CI, 0.74–1.21]; E vs. PTX: 14.1 vs. 10.8 months; HR, 1.00 [95% CI, 0.58–1.73]) and overall survival (E vs. DTX: not reached [NR] vs. NR; E vs. PTX: 75.5 months vs. NR) were similar among the subgroups. Although the incidences of adverse events (AEs) were generally similar, peripheral sensory neuropathy was more frequent with PTX and less frequent with DTX, compared with E. Neutropenia tended to be more frequent with E. Median time to QoL deterioration was longer with E vs. DTX (7.8 vs. 4.7 months) and E vs. PTX (6.1 vs. 3.9 months). Conclusions This trial revealed comparable efficacy of E vs. either DTX or PTX, when combined with dual HER2 blockade as first-line treatment for HER2+ LABC/MBC. AEs were generally similar between the E and T subgroups. QoL was maintained for longer in the E subgroups vs. T subgroups. Trial registration ClinicalTrials.gov (NCT03264547; registered: 28 June 2017); University Hospital Medical Information Network (UMIN000027938; registered: 26 June 2017). Graphical Abstract
- 8 July 2026
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 218 (1) , 3
Efficacy and safety of eribulin mesylate vs. docetaxel or paclitaxel, combined with trastuzumab and pertuzumab, as first-line treatment for HER2-positive locally advanced or metastatic breast cancer: updated subgroup analyses of JBCRG-M06/EMERALD
Purpose We performed updated subgroup analyses of the EMERALD study to investigate efficacy, safety, and quality of life (QoL) in patients treated with eribulin (E) vs. either docetaxel (DTX) or paclitaxel (PTX). Methods Patients with HER2+ locally advanced/metastatic breast cancer (LABC/MBC) were randomized to receive E or taxane (T) (physician’s choice of DTX or PTX; declared in advance at registration) in 21-day cycles, each combined with trastuzumab + pertuzumab. Survival outcomes, treatment patterns, antitumor efficacy, safety, and QoL were examined. Results The intention-to-treat (and safety) populations comprised 224 (224) patients who received E, 186 (184) who received DTX, and 36 (34) who received PTX. Baseline characteristics were balanced. Progression-free survival (E vs. DTX: 14.0 vs. 13.1 months; hazard ratio [HR], 0.94 [95% CI, 0.74–1.21]; E vs. PTX: 14.1 vs. 10.8 months; HR, 1.00 [95% CI, 0.58–1.73]) and overall survival (E vs. DTX: not reached [NR] vs. NR; E vs. PTX: 75.5 months vs. NR) were similar among the subgroups. Although the incidences of adverse events (AEs) were generally similar, peripheral sensory neuropathy was more frequent with PTX and less frequent with DTX, compared with E. Neutropenia tended to be more frequent with E. Median time to QoL deterioration was longer with E vs. DTX (7.8 vs. 4.7 months) and E vs. PTX (6.1 vs. 3.9 months). Conclusions This trial revealed comparable efficacy of E vs. either DTX or PTX, when combined with dual HER2 blockade as first-line treatment for HER2+ LABC/MBC. AEs were generally similar between the E and T subgroups. QoL was maintained for longer in the E subgroups vs. T subgroups. Trial registration ClinicalTrials.gov (NCT03264547; registered: 28 June 2017); University Hospital Medical Information Network (UMIN000027938; registered: 26 June 2017). Graphical Abstract
- 29 April 2026
- Published by Springer Nature in International Cancer Conference Journal
- Vol. 15 (3) , 1-4
Acinic cell carcinoma of the breast in a patient with a BRCA1 pathogenic variant: a case report
- 29 April 2026
- Published by Springer Nature in International Cancer Conference Journal
- Vol. 15 (3) , 1-4
Acinic cell carcinoma of the breast in a patient with a BRCA1 pathogenic variant: a case report
- Open Access
- 15 April 2026
- Published by Springer Nature in Breast Cancer Research
- Vol. 28 (1)
Dynamic changes in serum HER2-peptide-specific autoantibodies predict response to neoadjuvant therapy in HER2-positive breast cancer
Neoadjuvant chemotherapy (NAC) with anti-HER2 agents is standard for HER2-positive breast cancer, achieving pathological complete response (pCR) in 40–50% of patients; however, reliable predictors of response remain limited. HER2 is an immunogenic antigen capable of eliciting humoral responses, yet the predictive value of HER2-specific autoantibodies in the neoadjuvant setting remains unclear. We investigated whether HER2-peptide–specific antibody responses could serve as potential biomarkers of treatment response. Paired pre- and post-NAC sera from 112 patients enrolled in the JBCRG-16 (Neo-Lath) trial, which evaluated trastuzumab- and lapatinib-containing NAC, were analyzed. IgG titers against 63 non-overlapping 20-mer HER2-derived peptides were measured using a multiplex bead array, and serum HER2 protein levels were also quantified. Data were analyzed using Wilcoxon signed-rank and rank-sum tests, Spearman’s correlation analyses, and univariate logistic regression for pCR. Predictive models were constructed using elastic net regression with nested cross-validation across pretreatment, posttreatment, and fold-change datasets, and model performance was assessed by the area under the receiver operating characteristic curve (AUC). HER2-derived peptides elicited heterogeneous immune responses, and IgG titers against 37 of 63 peptides (58.7%) significantly decreased after NAC. Pretreatment IgG titers were positively correlated with the Boman index and negatively correlated with the aliphatic index. In univariate analyses, neither IgG titers nor serum HER2 levels at either time point, nor their treatment-induced changes, were significantly associated with pCR. In contrast, a predictive model based on treatment-induced changes in a subset of peptide-specific IgG titers demonstrated consistent predictive performance (AUC 0.78 in training and 0.79 in validation). Six peptides distributed across the HER2 sequence contributed to pCR prediction. Dynamic changes in HER2-peptide-specific autoantibodies during NAC, rather than static titers alone, may provide informative biomarkers for predicting clinical response. Serum HER2 levels were not significantly associated with pCR, suggesting that autoantibody profiling may capture response-related biology not reflected by antigen levels alone. These findings provide proof-of-concept evidence that minimally invasive, longitudinal profiling of peptide-specific autoantibodies could complement established response-assessment modalities, such as imaging or molecular assays. However, these results are exploratory and require validation in larger, independent cohorts before clinical application. UMIN000007576 (Registration date: March 26, 2012). The online version contains supplementary material available at 10.1186/s13058-026-02259-y.
- 15 April 2026
- Published by Springer Nature in Breast Cancer Research
- Vol. 28 (1)
Open AccessDynamic changes in serum HER2-peptide-specific autoantibodies predict response to neoadjuvant therapy in HER2-positive breast cancer
Neoadjuvant chemotherapy (NAC) with anti-HER2 agents is standard for HER2-positive breast cancer, achieving pathological complete response (pCR) in 40–50% of patients; however, reliable predictors of response remain limited. HER2 is an immunogenic antigen capable of eliciting humoral responses, yet the predictive value of HER2-specific autoantibodies in the neoadjuvant setting remains unclear. We investigated whether HER2-peptide–specific antibody responses could serve as potential biomarkers of treatment response. Paired pre- and post-NAC sera from 112 patients enrolled in the JBCRG-16 (Neo-Lath) trial, which evaluated trastuzumab- and lapatinib-containing NAC, were analyzed. IgG titers against 63 non-overlapping 20-mer HER2-derived peptides were measured using a multiplex bead array, and serum HER2 protein levels were also quantified. Data were analyzed using Wilcoxon signed-rank and rank-sum tests, Spearman’s correlation analyses, and univariate logistic regression for pCR. Predictive models were constructed using elastic net regression with nested cross-validation across pretreatment, posttreatment, and fold-change datasets, and model performance was assessed by the area under the receiver operating characteristic curve (AUC). HER2-derived peptides elicited heterogeneous immune responses, and IgG titers against 37 of 63 peptides (58.7%) significantly decreased after NAC. Pretreatment IgG titers were positively correlated with the Boman index and negatively correlated with the aliphatic index. In univariate analyses, neither IgG titers nor serum HER2 levels at either time point, nor their treatment-induced changes, were significantly associated with pCR. In contrast, a predictive model based on treatment-induced changes in a subset of peptide-specific IgG titers demonstrated consistent predictive performance (AUC 0.78 in training and 0.79 in validation). Six peptides distributed across the HER2 sequence contributed to pCR prediction. Dynamic changes in HER2-peptide-specific autoantibodies during NAC, rather than static titers alone, may provide informative biomarkers for predicting clinical response. Serum HER2 levels were not significantly associated with pCR, suggesting that autoantibody profiling may capture response-related biology not reflected by antigen levels alone. These findings provide proof-of-concept evidence that minimally invasive, longitudinal profiling of peptide-specific autoantibodies could complement established response-assessment modalities, such as imaging or molecular assays. However, these results are exploratory and require validation in larger, independent cohorts before clinical application. UMIN000007576 (Registration date: March 26, 2012). The online version contains supplementary material available at 10.1186/s13058-026-02259-y.
- Open Access
- 1 July 2024
- Published by Galenos Yayinevi in European Journal of Breast Health
- Vol. 20 (3) , 215-222
Retrospective Analysis of the Clinical Usefulness of a Strut-Adjusted Volume Implant in a Single Center
Retrospective Analysis of the Clinical Usefulness of a Strut-Adjusted Volume Implant in a Single Center - European Journal of Breast Health
- 1 July 2024
- Published by Galenos Yayinevi in European Journal of Breast Health
- Vol. 20 (3) , 215-222
Open AccessRetrospective Analysis of the Clinical Usefulness of a Strut-Adjusted Volume Implant in a Single Center
Retrospective Analysis of the Clinical Usefulness of a Strut-Adjusted Volume Implant in a Single Center - European Journal of Breast Health
- Open Access
- 21 November 2023
- Published by Springer Nature in Research Square
Retrospective Analysis of the Clinical Usefulness of a Strut-adjusted Volume Implant in a Single Center
Background: Reports demonstrating the effectiveness and safety of strut-adjusted volume implant (SAVI) in Japan are limited. Therefore, we aimed to compare the treatment outcomes of SAVI and whole breast irradiation (WBI) at a single facility. Methods: Data were retrospectively extracted from the medical records of patients treated with SAVI or WBI following breast-conserving therapy. Patients undergoing partial mastectomy (Bp), sentinel lymph node biopsy (SLNB), and SAVI spacer insertion followed by SAVI irradiation were compared to those followed by WBI. Local recurrence was assessed annually by physical examination, bilateral mammography, and breast ultrasonography. Results: The SAVI and WBI groups comprised 53 and 113 patients, with a median age of 55 and 52 years, respectively; among whom, 47 and 6 patients had pathological tumor diameter ≤ 2 cm and 91 and 22 had pathological tumor diameter > 2 cm, respectively. Micro-lymph node metastasis, recurrence events, and acute adverse events were observed in the SAVI and WBI groups in 2 and 2, 1 and 3, and 24 and 79 patients, respectively, with median observation periods of 60.0 and 47.8 months, respectively. All adverse events were grades 1–2, with dermatitis being the most common. In the late phase, pigmentation was common in both groups (24 and 18 patients in the SAVI and WBI groups, respectively). Cosmetic outcomes were excellent/good in 42 and 42 patients in the SAVI and WBI groups, respectively. Conclusions: SAVI is expected to benefit patients in the future. Large-scale studies are warranted to verify the usefulness of SAVI in Japan.
- 21 November 2023
- Published by Springer Nature in Research Square
Open AccessRetrospective Analysis of the Clinical Usefulness of a Strut-adjusted Volume Implant in a Single Center
Background: Reports demonstrating the effectiveness and safety of strut-adjusted volume implant (SAVI) in Japan are limited. Therefore, we aimed to compare the treatment outcomes of SAVI and whole breast irradiation (WBI) at a single facility. Methods: Data were retrospectively extracted from the medical records of patients treated with SAVI or WBI following breast-conserving therapy. Patients undergoing partial mastectomy (Bp), sentinel lymph node biopsy (SLNB), and SAVI spacer insertion followed by SAVI irradiation were compared to those followed by WBI. Local recurrence was assessed annually by physical examination, bilateral mammography, and breast ultrasonography. Results: The SAVI and WBI groups comprised 53 and 113 patients, with a median age of 55 and 52 years, respectively; among whom, 47 and 6 patients had pathological tumor diameter ≤ 2 cm and 91 and 22 had pathological tumor diameter > 2 cm, respectively. Micro-lymph node metastasis, recurrence events, and acute adverse events were observed in the SAVI and WBI groups in 2 and 2, 1 and 3, and 24 and 79 patients, respectively, with median observation periods of 60.0 and 47.8 months, respectively. All adverse events were grades 1–2, with dermatitis being the most common. In the late phase, pigmentation was common in both groups (24 and 18 patients in the SAVI and WBI groups, respectively). Cosmetic outcomes were excellent/good in 42 and 42 patients in the SAVI and WBI groups, respectively. Conclusions: SAVI is expected to benefit patients in the future. Large-scale studies are warranted to verify the usefulness of SAVI in Japan.
- Open Access
- 1 January 2023
- Published by Japanese Society for Palliative Medicine in Palliative Care Research
- Vol. 18 (1) , 11-18
Investigation of the Safety and Effectiveness of Metronidazole Gel (Rozex® gel 0.75%) on Sterilization and Reduction of Odor at Cancerous Skin Ulcer (Drug Use-results Survey)
【目的】メトロニダゾールゲル(ロゼックス®ゲル0.75%:以下,本剤)について,長期使用時を含む使用実態下の安全性と有効性に関する情報を収集する目的で使用成績調査を実施した.【方法】がん性皮膚潰瘍部位の殺菌・臭気の軽減のために本剤を初めて使用する患者を中央登録方式にて登録した.観察期間は最長1年とした.【結果】安全性解析対象は301例であった.副作用発現割合は3.32%(10/301例)で,すべて非重篤であった.全般改善割合は73.7%(205/278例)であった.最終観察時の医師評価によるにおい改善割合は80.2%(203/253例)で,患者の治療満足割合は70.1%(82/117例)であった.【結論】使用実態下において,本剤ががん性皮膚潰瘍部位の殺菌・臭気の軽減に対し,安全かつ有効な治療薬であるとともに,本剤の使用により,患者の高い治療満足度が得られることが明らかとなった.
- 1 January 2023
- Published by Japanese Society for Palliative Medicine in Palliative Care Research
- Vol. 18 (1) , 11-18
Open AccessInvestigation of the Safety and Effectiveness of Metronidazole Gel (Rozex® gel 0.75%) on Sterilization and Reduction of Odor at Cancerous Skin Ulcer (Drug Use-results Survey)
【目的】メトロニダゾールゲル(ロゼックス®ゲル0.75%:以下,本剤)について,長期使用時を含む使用実態下の安全性と有効性に関する情報を収集する目的で使用成績調査を実施した.【方法】がん性皮膚潰瘍部位の殺菌・臭気の軽減のために本剤を初めて使用する患者を中央登録方式にて登録した.観察期間は最長1年とした.【結果】安全性解析対象は301例であった.副作用発現割合は3.32%(10/301例)で,すべて非重篤であった.全般改善割合は73.7%(205/278例)であった.最終観察時の医師評価によるにおい改善割合は80.2%(203/253例)で,患者の治療満足割合は70.1%(82/117例)であった.【結論】使用実態下において,本剤ががん性皮膚潰瘍部位の殺菌・臭気の軽減に対し,安全かつ有効な治療薬であるとともに,本剤の使用により,患者の高い治療満足度が得られることが明らかとなった.
- Open Access
- 29 June 2022
- Published by Springer Nature in Breast Cancer
- Vol. 29 (6) , 1013-1021
Diagnostic performance of dedicated breast positron emission tomography
Background: Dedicated breast positron emission tomography (dbPET) has been developed for detecting smaller breast cancer. We investigated the diagnostic performance of dbPET in patients with known breast cancer. Methods: Eighty-two preoperative patients with breast cancer were included in the study (84 tumours: 11 ductal carcinomas in situ [DCIS], 73 invasive cancers). They underwent mammography (MMG), ultrasonography (US), and contrast-enhanced breast magnetic resonance imaging (MRI) before whole-body PET/MRI (WBPET/MRI) and dbPET. We evaluated the sensitivity of all modalities, and the association between the maximum standard uptake value (SUVmax) level and histopathological features. Results: The sensitivities of MMG, US, MRI, WBPET/MRI and dbPET for all tumours were 81.2% (65/80), 98.8% (83/84), 98.6% (73/74), 86.9% (73/84), and 89.2% (75/84), respectively. For 11 DCIS and 22 small invasive cancers (≤ 2 cm), the sensitivity of dbPET (84.9%) tended to be higher than that of WBPET/MRI (69.7%) (p = 0.095). Seven tumours were detected by dbPET only, but not by WBPET/MRI. Five tumours were detected by only WBPET/MRI because of the blind area of dbPET detector, requiring a wider field of view. After making the mat of dbPET detector thinner, all 22 scanned tumours were depicted. The higher SUVmax of dbPET was significantly related to the negative oestrogen receptor status, higher nuclear grade, and higher Ki67 (p < 0.001). Conclusions: The sensitivity of dbPET for early breast cancer was higher than that of WBPET/MRI. High SUVmax was related to aggressive features of tumours. Moreover, dbPET can be used for the diagnosis and oncological evaluation of breast cancer.
- 29 June 2022
- Published by Springer Nature in Breast Cancer
- Vol. 29 (6) , 1013-1021
Open AccessDiagnostic performance of dedicated breast positron emission tomography
Background: Dedicated breast positron emission tomography (dbPET) has been developed for detecting smaller breast cancer. We investigated the diagnostic performance of dbPET in patients with known breast cancer. Methods: Eighty-two preoperative patients with breast cancer were included in the study (84 tumours: 11 ductal carcinomas in situ [DCIS], 73 invasive cancers). They underwent mammography (MMG), ultrasonography (US), and contrast-enhanced breast magnetic resonance imaging (MRI) before whole-body PET/MRI (WBPET/MRI) and dbPET. We evaluated the sensitivity of all modalities, and the association between the maximum standard uptake value (SUVmax) level and histopathological features. Results: The sensitivities of MMG, US, MRI, WBPET/MRI and dbPET for all tumours were 81.2% (65/80), 98.8% (83/84), 98.6% (73/74), 86.9% (73/84), and 89.2% (75/84), respectively. For 11 DCIS and 22 small invasive cancers (≤ 2 cm), the sensitivity of dbPET (84.9%) tended to be higher than that of WBPET/MRI (69.7%) (p = 0.095). Seven tumours were detected by dbPET only, but not by WBPET/MRI. Five tumours were detected by only WBPET/MRI because of the blind area of dbPET detector, requiring a wider field of view. After making the mat of dbPET detector thinner, all 22 scanned tumours were depicted. The higher SUVmax of dbPET was significantly related to the negative oestrogen receptor status, higher nuclear grade, and higher Ki67 (p < 0.001). Conclusions: The sensitivity of dbPET for early breast cancer was higher than that of WBPET/MRI. High SUVmax was related to aggressive features of tumours. Moreover, dbPET can be used for the diagnosis and oncological evaluation of breast cancer.
- Open Access
Magnetically Guided Localization Using a Guiding-Marker System® and a Handheld Magnetic Probe for Nonpalpable Breast Lesions: A Multicenter Feasibility Study in Japan
Accurate pre-operative localization of nonpalpable lesions plays a pivotal role in guiding breast-conserving surgery (BCS). In this multicenter feasibility study, nonpalpable breast lesions were localized using a handheld magnetic probe (TAKUMI) and a magnetic marker (Guiding-Marker System®). The magnetic marker was preoperatively placed within the target lesion under ultrasound or stereo-guidance. Additionally, a dye was injected subcutaneously to indicate the extent of the tumor excision. Surgeons checked for the marker within the lesion using a magnetic probe. The magnetic probe could detect the guiding marker and accurately localize the target lesion intraoperatively. All patients with breast cancer underwent wide excision with a safety margin of ≥5 mm. The presence of the guiding-marker within the resected specimen was the primary outcome and the pathological margin status and re-excision rate were the secondary outcomes. Eighty-seven patients with nonpalpable lesions who underwent BCS, from January to March of 2019 and from January to July of 2020, were recruited. The magnetic marker was detected in all resected specimens. The surgical margin was positive only in 5/82 (6.1%) patients; these patients underwent re-excision. This feasibility study demonstrated that the magnetic guiding localization system is useful for the detection and excision of nonpalpable breast lesions.
Open AccessMagnetically Guided Localization Using a Guiding-Marker System® and a Handheld Magnetic Probe for Nonpalpable Breast Lesions: A Multicenter Feasibility Study in Japan
Accurate pre-operative localization of nonpalpable lesions plays a pivotal role in guiding breast-conserving surgery (BCS). In this multicenter feasibility study, nonpalpable breast lesions were localized using a handheld magnetic probe (TAKUMI) and a magnetic marker (Guiding-Marker System®). The magnetic marker was preoperatively placed within the target lesion under ultrasound or stereo-guidance. Additionally, a dye was injected subcutaneously to indicate the extent of the tumor excision. Surgeons checked for the marker within the lesion using a magnetic probe. The magnetic probe could detect the guiding marker and accurately localize the target lesion intraoperatively. All patients with breast cancer underwent wide excision with a safety margin of ≥5 mm. The presence of the guiding-marker within the resected specimen was the primary outcome and the pathological margin status and re-excision rate were the secondary outcomes. Eighty-seven patients with nonpalpable lesions who underwent BCS, from January to March of 2019 and from January to July of 2020, were recruited. The magnetic marker was detected in all resected specimens. The surgical margin was positive only in 5/82 (6.1%) patients; these patients underwent re-excision. This feasibility study demonstrated that the magnetic guiding localization system is useful for the detection and excision of nonpalpable breast lesions.
- Open Access
- 1 February 2015
- Published by Elsevier in Clinical Breast Cancer
- Vol. 15 (1) , 80-85
BRCAness Predicts Resistance to Taxane-Containing Regimens in Triple Negative Breast Cancer During Neoadjuvant Chemotherapy
- 1 February 2015
- Published by Elsevier in Clinical Breast Cancer
- Vol. 15 (1) , 80-85
Open AccessBRCAness Predicts Resistance to Taxane-Containing Regimens in Triple Negative Breast Cancer During Neoadjuvant Chemotherapy